SCHEMBL3203494

SCHEMBL3203494

COc1ccc(NC(=O)c2ccc(Cl)c(-c3cccnc3)c2)cn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.63
ROCK2 O75116 2/20 0.59
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
KEAP1 Q14145 1/20 0.57
NFE2L2 Q16236 1/20 0.57
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
CSF1R P07333 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
LMNA P02545 1/20 0.52
NAMPT P43490 2/20 0.52
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL775233 0.96 ROCK2 (0.65) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL3200374 0.89 ABL1 (0.55) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL777653 0.88 MEN1 (0.64) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL775239 0.88 ROCK2 (0.61) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL775321 0.87 MEN1 (0.64) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL775208 0.87 KMT2A (0.64) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL773257 0.87 MEN1 (0.56) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL775074 0.86 NPC1 (0.62) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL775009 0.86 MEN1 (0.63) ABL1ROCK2KMT2AMEN1KEAP1
SCHEMBL3218441 0.85 CLK2 (0.57) ABL1ROCK2KMT2AMEN1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B ABL1 1015/4885ROCK2 846/4885KMT2A 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.